Electromotive delivery of mitomycin C into human bladder wall

Area of Science:

• Oncology
• Pharmacology
• Biomedical Engineering

Background:

• Bladder cancer treatment often involves localized drug delivery.
• Optimizing drug penetration and consistency in the bladder wall is crucial for efficacy.
• Current drug delivery methods may have limitations in achieving uniform tissue concentrations.

Purpose of the Study:

• To develop a pharmacokinetic model for mitomycin C (MMC) in human bladder tissue.
• To compare MMC concentrations delivered via passive diffusion versus electromotive administration (EMDA).
• To assess the impact of EMDA on bladder tissue morphology and MMC integrity.

Main Methods:

• Human bladder tissue sections were used in a two-compartment cell system.
• MMC was administered with an anode in the donor compartment and a cathode in the receptor compartment.
• Experiments compared 15-minute applications of 5 mA current versus no current.
• MMC tissue content was quantified using high-pressure liquid chromatography.
• Tissue viability, morphology, and MMC stability were assessed via multiple analytical techniques.

Main Results:

• EMDA significantly increased MMC concentrations within bladder tissue samples.
• EMDA reduced the variability in the rate of drug delivery across tissue samples.
• Histological analysis confirmed tissue viability and structural integrity post-EMDA.
• Mass spectrometry showed no structural degradation of MMC following EMDA.

Conclusions:

• EMDA is an effective method for enhancing MMC administration into viable human bladder wall tissue.
• EMDA improves drug delivery consistency, reducing variability compared to passive methods.
• The technique preserves tissue health and the structural integrity of the chemotherapeutic agent.